Novel 2-alkyl-1α,25-dihydroxy-19-norvitamin D3: Efficient synthesis with Julia olefination, evaluation of biological activity and development of new analyzing system for co-activator recruitment

Anticancer Research

Volumn 26, Issue 4 A, 2006, Pages 2621-2631

  Arai, Midori A ^a   Kittaka, Atsushi ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

19 norvitamin D3; Co activator; High throughput screening; Julia olefination; Synthesis; Vitamin D receptor

Indexed keywords

2ALPHA ALLYL 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; 2ALPHA PROPYL 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; 2ALPHA(3 HYDROXYPROLYL) 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; 2BETA(3 HYDROXYPROLYL) 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; ALKADIENE; CARBON; CYCLOHEXANONE DERIVATIVE; HORMONE; KETONE; LIGAND; QUINIC ACID; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ALLYLATION; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL DIFFERENTIATION; CONFORMATION; CONTROLLED STUDY; COW; DEPROTECTION REACTION; DIASTEREOISOMER; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NUCLEAR OVERHAUSER EFFECT; OLEFINATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; STEREOCHEMISTRY; THYMUS;

ALKYLATION; ANIMALS; CALCITRIOL; CATTLE; CELL DIFFERENTIATION; CYCLOHEXANONES; HL-60 CELLS; HUMANS; KINETICS; MOLECULAR CONFORMATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; QUINIC ACID; RECEPTORS, CALCITRIOL; SWINE;

EID: 33746593835     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Nishii Y and Okano T: History of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy) calcitriol (ED-71). Steroids 66: 137-146, 2001.
2. Kubodera N: Development of OCT and ED-71. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1525-1541, 2005.
3. Reichrath J and Holick MF: Psoriasis and other skin diseases. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1791-1804, 2005.
4. 3 accessible to vitamin D receptor mutant related to hereditary vitamin D-resistant rickets. Chem Pharm Bull 57: 357-358, 2003.
5. 3. J Biol Chem 276: 29148-29156, 2001.
6. 3 analogues which selectively restore activity to a vitamin D receptor mutant associated with rickets. Org Lett 4: 3863-3866, 2002.
7. Swann SL, Bergh J, Farach-Carson MC, Ocasio CA and Koh JT: Structure-based design of selective agonists for a rickets-associated mutant of the vitamin D receptor. J Am Chem Soc 124: 13795-13805, 2002.
8. Malloy PJ, Pike JW and Feldman D: Hereditary 1,25-dihydroxyvitamin D resistant rickets. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1207-1237, 2005.
9. Bouillon R, Okamura WH and Norman AW: Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257, 1995.
10. Binderup L, Binderup E, Godtfredsen WO and Kissmeyer A-M: Development of new vitamin D analogs. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1489-1510, 2005.
11. Uskokovic MR, Maehr H, Reddy SG, Li YC, Adorini L and Holick MF: Gemini: the 1,25-dihydroxy vitamin D analogs with two side-chains. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1511-1524, 2005.
12. Schwartz GG and Chen TC: Vitamin D, sunlight, and the natural history of prostate cancer. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1599-1615, 2005.
13. Colston K and Welsh J: Vitamin D and breast cancer. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1663-1677, 2005.
14. Krishnan A-V, Peehl DM and Feldman D: Vitamin D and prostate cancer. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1679-1707, 2005.
15. Cross HS: Vitamin D and colon cancer. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1709-1725, 2005.
16. 3 and its 20-epimer. Biochem Pharm 60: 1937-1947, 2000.
17. 3 analogs. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1405-1422, 2005.
18. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
19. 3. Bioorg Med Chem Lett 8: 151-156, 1998.
20. 3 and their 20-epimers: unique activity profiles depending on the stereochemistry of the A-ring and at C-20. J Med Chem 43: 4247-4265, 2000.
21. 3 analogues and their docking to vitamin D receptors. J Org Chem 66: 8760-8771, 2001.
22. 3 analogues. Bioorg Med Chem Lett 10:1129-1132, 2000.
23. 3 analogues with a double side chain: marked cell differentiation activity. Bioorg Med Chem Lett 12: 3255-3258, 2002.
24. 3. Bioorg Med Chem Lett 13: 3503-3506, 2003.
25. 3 analogues possessing aromatic ring on 2α-position. Tetrahedron 61: 11253-11263, 2005.
26. 3: remarkably high affinity to vitamin D receptor. Org Lett 2: 2619-2622, 2000.
27. 3. In: Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects. Norman AW, Bouillon R and Thomasset M (eds.). University of California, Riverside, Printing and Reprographics, pp. 49-52, 2000.
28. 3 analogues, including 2-epi-ED-71 and their 20-epimers with HL-60 cell differentiation activity. J Org Chem 69: 7463-7471, 2004.
29. 3. J Synth Org Chem Japan 60: 370-381, 2002.
30. 3 analogs. In: Vitamin D Analogs in Cancer Prevention and Therapy, Recent Results in Cancer Research 164. Reichrath J, Friedrich M and Tilgen W (eds.). Berlin Heidelberg, Springer-Verlag, pp. 289-317, 2003.
31. 3: A-ring structural motif that modulates interactions of vitamin D receptor with transcriptional coactivators. Org Biomol Chem 1: 1863-1869, 2003.
32. 3, the potent inducers of cell differentiation. J Steroid Biochem Mol Biol 89-90: 89-92, 2004.
33. 3, a novel vitamin D-related compound with potential therapeutic activity. Tetrahedron Lett 31: 1823-1824, 1990.
34. Perlman KL, Swenson RE, Paaren HE, Schnoes HK and DeLuca HF: Novel synthesis of 19-nor-vitamin D compounds. Tetrahedron Lett 32: 7663-7666, 1991.
35. 3: synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. J Med Chem 45: 3366-3380, 2002.
36. Mikami K, Osawa A, Isaka A, Terada M and Okano T: "Symmetry" in the synthesis of the A-ring of a vitamin D hybrid analog with significant transactivation activity: a combinatorial sequence of regioselective propiolate-ene, catalytic enantioselective epoxidation and carbonyl-ene cyclization reactions. Tetrahedron Lett 39: 3359-3362, 1998.
37. 3 A-ring analogs in cancer cell differentiation and apoptosis. Chem Biol 7: 173-184, 2000.
38. 3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogs. J Med Chem 41: 4662-4674, 1998.
39. 3. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1543-1555, 2005.
40. 3 with 3'-alkoxypropylidene moiety at C-2: synthesis, biological activity and conformational analysis. J Steroid Biochem Mol Biol 89-90: 25-30, 2004.
41. Mikami K, Koizumi Y, Osawa A, Terada M, Takayama H, Nakagawa K and Okano T: BINOL-Ti-catalyzed carbonyl-ene cyclization by tuning the 6-Br-ligand for the synthesis of 2-methyl-19-nor-22-oxa vitamin D analog with significant differentiation activity. Synlett 1899-1902, 1999.
42. Shimizu M, Iwasaki Y, Shibamoto Y, Sato M, DeLuca HF and Yamada S: Novel synthesis of 2-substituted 19-norvitamin D A-ring phosphine oxide from D-glucose as a building block. Bioorg Med Chem Lett 10: 809-812, 2003.
43. Shimizu M, Yamamoto K, Mihori M, Iwasaki Y, Morimoto D and Yamada S: Two-dimensional alanine scanning mutational analysis of the interaction between the vitamin D receptor and its ligands: studies of A-ring modified 19-norvitamin D analogs. J Steroid Biochem Mol Biol 89-90: 75-81, 2004.
44. 3 with two substituents at C-2: synthesis and biological activity. Bioorg Med Chem Lett 75: 1451-1455, 2005.
45. Zhou X, Zhu G-D, Van Haver D, Vandewalle M, De Clercq PJ, Verstuyf A and Bouillon R: Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1α,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20. J Med Chem 42: 3539-3556, 1999.
46. 3. J Med Chem 37: 3730-3738, 1994.
47. 3 to its 1,25-dihydroxy metabolite. Tetrahedron Lett 32: 6057-6060, 1991.
48. 3. Bioorg Med Chem Lett 5: 159-162, 1995.
49. 3: chemistry and biology. Bioorg Med Chem 10: 2353-2365, 2002.
50. 3 derivative. Tetrahedron 57: 681-694, 2001.
51. Baudin JB, Hareau G, Julia SA and Ruel O: A direct synthesis of olefins by the reaction of carbonyl compounds with lithio derivatives of 2-[alkyl- or 2'-alkenyl- or benzylsulfonyl] benzothiazoles. Tetrahedron Lett 32: 1175-1178, 1991.
52. Trost BM, Dumas J and Villa M: New strategies for the synthesis of vitamin D metabolites via palladium-catalyzed reactions. J Am Chem Soc 114: 9836-9845, 1992.
53. 3 with Julia olefination: high potency in induction of differentiation on HL-60 cells. J Org Chem 83: 7407-7415, 2003.
54. 3 analogues. Synlett 8: 1175-1179, 2003.
55. Imae Y, Manaka A, Yoshida N, Ishimi Y, Shinki T, Abe E, Suda T, Konno K, Takayama H and Yamada S: Biological activities of 24-fluoro-1α,25- dihydroxyvitamin D-2 and its 24-epimer. Biochim Biophys Acta 1213: 302-308, 1994.
56. 3 with side-chain modifications. Bioorg Med Chem 9: 525-535, 2001.
57. Collins SJ, Ruscetti FW, Gallagher RE and Gallo RC: Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med 149: 969-974, 1979.
58. 3. J Med Chem 45: 1825-1834, 2002.
59. For the X-ray crystallographic analyses of the VDR-LBD, see: Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D: The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 5: 173-179, 2000.
60. 3 hormone analogs and a LXXLL-contg. coactivator peptide. Biochemistry 43: 4101-4110, 2004.
61. Rochel N and Moras D: VDR LBD crystal structures. In: Vitamin D. Feldman D, Pike JW, Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 279-289, 2005.
62. Takeyama K-I, Masuhiro Y, Fuse H, Endo H, Murayama A, Kitanaka S, Suzawa M, Yanagisawa J and Kato S: Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 19: 1049-1055, 1999.
63. Kim Y-K, Arai MA, Arai T, Lamenzo JO, Dean III EF, Pattersin N, Clemons PA and Schreiber SL: Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. J Am Chem Soc 126: 14740-14745, 2004.
64. Kanoh N, Honda K, Simizu S, Muroi M and Osada H: Photocross-linked small-molecule affinity matrix for facilitating forward and reverse chemical genetics. Angew Chem Int Ed 44: 3559-3562, 2005.
65. Kanayama T, Mamiya S, Nishihara T and Nishikawa J-I: Basis of a high-throughput method for nuclear receptor ligands. J Biochem 133: 791-797, 2003.
66. HCHO is usually used to fix the tissues of animals, which is thought to make methylene bridges between proteins.
67. Arai MA, Takeyama K-I, Ito S, Kato S, Chen TC and Kittaka A, submitted.